J. Michael McIntosh

J. Michael McIntosh, MD

Languages spoken: English

Clinical Locations

University of Utah Hospital

Psychiatry
801-581-7951

  • J. Michael McIntosh, MD, graduated from the University of California at Los Angeles Medical School, completed residency training at the University of Colorado and is board-certified in general adult psychiatry. He is Professor with tenure in the Department of Psychiatry and Research Professor in the Department of Biology. Dr. McIntosh is also the Medical Director of the SLVAMC Behavioral Health Clinic where he sees medically complex patients with co-morbid psychiatric conditions. He is ranked by US News and World Reports among the top 1% of doctors in the United States.

    Specialties

    Board Certification

    American Board of Psychiatry & Neurology (Psychiatry)

  • J. Michael McIntosh, MD, graduated from the University of California at Los Angeles Medical School, completed residency training at the University of Colorado and is board-certified in general adult psychiatry. He is Professor with tenure in the Department of Psychiatry and Research Professor in the Department of Biology. Dr. McIntosh is also the Medical Director of the SLVAMC Behavioral Health Clinic where he sees medically complex patients with co-morbid psychiatric conditions. He is ranked by US News and World Reports among the top 1% of doctors in the United States.

    Board Certification and Academic Information

    Academic Departments Psychiatry -Primary
    Academic Divisions Adult Psychiatry
    Board Certification
    American Board of Psychiatry & Neurology (Psychiatry)

    Education history

    Residency Psychiatry - University of Utah School of Medicine Resident
    Psychiatry - University of Colorado at Denver and Health Sciences Center Resident
    Internship Psychiatry - University of Colorado at Denver and Health Sciences Center Intern
    Medicine - University of California - Los Angeles M.D.
    Undergraduate Biology - University of Utah B.S.

    Selected Publications

    Journal Article

    1. Richter K, Papke RL, Stokes C, Roy DC, Espinosa ES, Wolf PMK, Hecker A, Liese J, Singh VK, Padberg W, Schlter KD, Rohde M, McIntosh JM, Morley BJ, Horenstein NA, Grau V, Simard AR (2022). Comparison of the Anti-inflammatory Properties of Two Nicotinic Acetylcholine Receptor Ligands, Phosphocholine and pCF3-diEPP. Front Cell Neurosci, 16, 779081.
    2. Edinger F, Schmitt C, Koch C, McIntosh JM, Janciauskiene S, Markmann M, Sander M, Padberg W, Grau V (2021). Application of alpha1-antitrypsin in a rat model of veno-arterial extracorporeal membrane oxygenation. Sci Rep, 11(1), 15849.
    3. Fisher F, Zhang Y, Vincent PFY, Gajewiak J, Gordon TJ, Glowatzki E, Fuchs PA, McIntosh JM (2021). Cy3-RgIA-5727 Labels and Inhibits α9-Containing nAChRs of Cochlear Hair Cells. Front Cell Neurosci, 15, 697560.
    4. Paguigan ND, Tun JO, Leavitt LS, Lin Z, Chase K, Dowell C, Deering-Rice CE, Lim AL, Karthikeyan M, Hughen RW, Zhang J, Peterson RT, Reilly CA, Light AR, Raghuraman S, McIntosh JM, Olivera BM, Schmidt EW (2021). Nicotinic Acetylcholine Receptor Partial Antagonist Polyamides from Tunicates and Their Predatory Sea Slugs. ACS Chem Neurosci, 12(14), 2693-2704.
    5. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM (2021). Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. J Med Chem, 64(13), 9271-9278.
    6. Sethuramanujam S, Matsumoto A, deRosenroll G, Murphy-Baum B, Grosman C, McIntosh JM, Jing M, Li Y, Berson D, Yonehara K, Awatramani GB (2021). Rapid multi-directed cholinergic transmission in the central nervous system. Nat Commun, 12(1), 1374.
    7. Richter K, Ogiemwonyi-Schaefer R, Wilker S, Chaveiro AI, Agn A, Hecker M, Reichert M, Amati AL, Schlter KD, Manzini I, Schmalzing G, McIntosh JM, Padberg W, Grau V, Hecker A (2020). Amyloid Beta Peptide (Aβ1-42) Reverses the Cholinergic Control of Monocytic IL-1β Release. J Clin Med, 9(9).
    8. Yu Z, McIntosh JM, Sadeghi SG, Glowatzki E (2020). Efferent synaptic transmission at the vestibular type II hair cell synapse. J Neurophysiol, 124(2), 360-374.
    9. Bjrn-Yoshimoto WE, Ramiro IBL, Yandell M, McIntosh JM, Olivera BM, Ellgaard L, Safavi-Hemami H (2020). Curses or Cures: A Review of the Numerous Benefits Versus the Biosecurity Concerns of Conotoxin Research. Biomedicines, 8(8).
    10. Hone AJ, Rueda-Ruzafa L, Gordon TJ, Gajewiak J, Christensen S, Dyhring T, Albillos A, McIntosh JM (2020). Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists. J Neurochem, 154(2), 158-176.
    11. Rybin MJ, OBrien H, Ramiro IBL, Azam L, McIntosh JM, Olivera BM, Safavi-Hemami H, Yoshikami D (2020). αM-Conotoxin MIIIJ Blocks Nicotinic Acetylcholine Receptors at Neuromuscular Junctions of Frog and Fish. Toxins (Basel), 12(3).
    12. Donvito G, Muldoon PP, Jackson KJ, Ahmad U, Zaveri NT, McIntosh JM, Chen X, Lichtman AH, Damaj MI (2018). Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies. Addict Biol, 25(1), e12691.
    13. Huynh PN, Giuvelis D, Christensen S, Tucker KL, McIntosh JM (2019). RgIA4 Accelerates Recovery from Paclitaxel-Induced Neuropathic Pain in Rats. Mar Drugs, 18(1).
    14. van Hout M, Valdes A, Christensen SB, Tran PT, Watkins M, Gajewiak J, Jensen AA, Olivera BM, McIntosh JM (2019). α-Conotoxin VnIB from Conus ventricosus is a potent and selective antagonist of α6β4* nicotinic acetylcholine receptors. Neuropharmacology, 157, 107691.
    15. Peng C, Yan Y, Kim VJ, Engle SE, Berry JN, McIntosh JM, Neve RL, Drenan RM (2018). Gene editing vectors for studying nicotinic acetylcholine receptors in cholinergic transmission. Eur J Neurosci, 50(3), 2224-2238.
    16. Zakrzewicz A, Richter K, Zakrzewicz D, Siebers K, Damm J, Agn A, Hecker A, McIntosh JM, Chamulitrat W, Krasteva-Christ G, Manzini I, Tikkanen R, Padberg W, Janciauskiene S, Grau V (2019). SLPI Inhibits ATP-Mediated Maturation of IL-1β in Human Monocytic Leukocytes: A Novel Function of an Old Player. Front Immunol, 10, 664.
    17. Grau V, Richter K, Hone AJ, McIntosh JM (2019). Conopeptides [V11L;V16D]ArIB and RgIA4: Powerful Tools for the Identification of Novel Nicotinic Acetylcholine Receptors in Monocytes. Front Pharmacol, 9, 1499.
    18. Arribas-Blzquez M, Olivos-Or LA, Barahona MV, Snchez de la Muela M, Solar V, Jimnez E, Gualix J, McIntosh JM, Ferrer-Montiel A, Miras-Portugal MT, Artalejo AR (2019). Overexpression of P2X3 and P2X7 Receptors and TRPV1 Channels in Adrenomedullary Chromaffin Cells in a Rat Model of Neuropathic Pain. Int J Mol Sci, 20(1).
    19. Richter K, Koch C, Perniss A, Wolf PM, Schweda EKH, Wichmann S, Wilker S, Magel I, Sander M, McIntosh JM, Padberg W, Grau V (2018). Phosphocholine-Modified Lipooligosaccharides of Haemophilus influenzae Inhibit ATP-Induced IL-1β Release by Pulmonary Epithelial Cells. Molecules, 23(8).
    20. Mucchietto V, Fasoli F, Pucci S, Moretti M, Benfante R, Maroli A, Di Lascio S, Bolchi C, Pallavicini M, Dowell C, McIntosh M, Clementi F, Gotti C (2017). α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. Br J Pharmacol, 175(11), 1957-1972.
    21. Yan Y, Peng C, Arvin MC, Jin XT, Kim VJ, Ramsey MD, Wang Y, Banala S, Wokosin DL, McIntosh JM, Lavis LD, Drenan RM (2017). Nicotinic Cholinergic Receptors in VTA Glutamate Neurons Modulate Excitatory Transmission. Cell Rep, 23(8), 2236-2244.
    22. Siebers K, Fink B, Zakrzewicz A, Agn A, Richter K, Konzok S, Hecker A, Zukunft S, Kllmar M, Klein J, McIntosh JM, Timm T, Sewald K, Padberg W, Aggarwal N, Chamulitrat W, Santoso S, Xia W, Janciauskiene S, Grau V (2018). Alpha-1 Antitrypsin Inhibits ATP-Mediated Release of Interleukin-1β via CD36 and Nicotinic Acetylcholine Receptors. Front Immunol, 9, 877.
    23. Pang X, Liu L, Ngolab J, Zhao-Shea R, McIntosh JM, Gardner PD, Tapper AR (2016). Habenula cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic acetylcholine receptors. Neuropharmacology, 107, 294-304.
    24. Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M (2015). α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord, 30(14), 1901-1911.

    Patent

    1. J. Michael MCINTOSH, Baldomero M. OLIVERA, Michael ELLISON, Michelle A. VINCLER (2012). CONOTOXIN PEPTIDES. U.S. Patent No. 20120220539. Washington, D.C.:U.S. Patent and Trademark Office.
    2. McIntosh JM (2012). Alpha-conotoxin Peptides. U.S. Patent No. US 8110549 B2. Washington, D.C.:U.S. Patent and Trademark Office.
    3. McIntosh, JM (2012). Alpha-conotoxin Analogs. U.S. Patent No. US 8101,573 B2. Washington, D.C.:U.S. Patent and Trademark Office.
    4. McIntosh, JM (2011). Alpha-conotoxin Peptides. U.S. Patent No. US 7902153 B. Washington, D.C.:U.S. Patent and Trademark Office.
    5. Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM (2007). Alpha-conotoxin peptides. U.S. Patent No. United States Patent 7279549. Washington, D.C.:U.S. Patent and Trademark Office.
    6. Olivera BM, Layer RT, McIntosh JM, Nielsen JS, Jones RM (2005). .alpha.-conotoxin peptides. U.S. Patent No. 6,855,805. Washington, D.C.:U.S. Patent and Trademark Office.
    7. Walker CS, Shetty R, Jimenez EC, McIntosh JM, Olivera BM, Watkins M, Jones RM, Shen GS (2004). I-superfamily conotoxins. U.S. Patent No. 6,767,895. Washington, D.C.:U.S. Patent and Trademark Office.
    8. McIntosh JM, et al (2004). Alpha-Conotoxin Peptides (Australia). U.S. Patent No. 770,076. Washington, D.C.:U.S. Patent and Trademark Office.
    9. Olivera BM, Cartier GE, Watkins M, Hillyard DR, McIntosh JM, Layer RT, Jones RM (2004). O-superfamily conotoxin peptides. U.S. Patent No. 6,762,165. Washington, D.C.:U.S. Patent and Trademark Office.
    10. Olivera BM, McIntosh JM, McCabe RT, Layer RT, Zhou L-M (2001). Use of conantokins for treating pain. U.S. Patent No. 6,277,825. Washington, D.C.:U.S. Patent and Trademark Office.
    11. Olivera BM, Layer RT, Watkins M, Hillyard DR, McIntosh JM, Schoenfeld R, Jones RM (2001). .alpha.-conotoxin peptides. U.S. Patent No. 6,268,473. Washington, D.C.:U.S. Patent and Trademark Office.
    12. Shon K-J, Olivera BM, McIntosh JM (1999). Conotoxin peptides. U.S. Patent No. 5,990,295. Washington, D.C.:U.S. Patent and Trademark Office.
    13. McIntosh JM, Kulak JM, Yoshikami D, Olivera BM (1999). Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release. U.S. Patent No. 5,922,679. Washington, D.C.:U.S. Patent and Trademark Office.
    14. Cruz LJ, Olivera BM, McIntosh JM, Jimenez E, Craig AG, Rivier JA, Julius D, England L (1999). Bromo-tryptophan conopeptides. U.S. Patent No. 5,889,147. Washington, D.C.:U.S. Patent and Trademark Office.
    15. McIntosh JM, Cartier GE, Yoshikami D, Luo S, Olivera BM (1999). Conopeptides AuIA, AuIB and AuIC. U.S. Patent No. 5,866,682. Washington, D.C.:U.S. Patent and Trademark Office.
    16. McIntosh JM, Kulak JM, Yoshikami D, Olivera BM (1998). Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release. U.S. Patent No. 5,780,433. Washington, D.C.:U.S. Patent and Trademark Office.
    17. Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AO (1997). Conotoxin peptides. U.S. Patent No. 5,633,347. Washington, D.C.:U.S. Patent and Trademark Office.
    18. Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AD (1997). Conotoxin peptides. U.S. Patent No. 5,595,972. Washington, D.C.:U.S. Patent and Trademark Office.
    19. Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AD (1996). Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides. U.S. Patent No. 5,589,340. Washington, D.C.:U.S. Patent and Trademark Office.
    20. Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AD (1996). Conotoxin Peptides. U.S. Patent No. 5,514,774. Washington, D.C.:U.S. Patent and Trademark Office.

  • Podcasts & News

    News

    The Scope Podcast